The Anticancer Fund welcomes new members in the Advisory Board
The Anticancer Fund announces the formation of a new Advisory Board, who will help shape and guide the strategy of our organisation. The board includes distinguished scientists, clinicians and patient representatives active in the cancer field.
The Anticancer Fund relies on a group of experts for scientific and strategic advice. The Advisory Board meets twice a year and provides input to the board of directors. Their assistance is also sought on an ad hoc basis depending on their area of expertise. The members of the Advisory Board deliver their consultancy services pro bono.
‘We are thrilled to announce the appointment of new Advisory Board members that will strengthen our organisation. Beating cancer is a challenge and we are very thankful these eminent experts help us to fulfil our mission’, said Lydie Meheus, Managing Director of the Anticancer Fund.
The Advisory Board (in alphabetical order):
Prof. Dr. Bert Aertgeerts, MD, PhD
Bert Aertgeerts is a general practitioner and one of the founding members of the Belgian Centre for Evidence-Based Medicine (Belgian Cochrane Centre). As a full professor at the University of Leuven (KU Leuven), Belgium, he is responsible for the scientific programme within the medical curriculum. He is a member of the Board of the Faculty of Medicine and of the Council of the Department of Public Health and Primary Care. He is also Head of the Department for Primary Care at the KU Leuven. His research shifted from alcohol screening and diagnostic topics in his early years to Evidence-Based Medicine and implementation of evidence into clinical practice. Prof. Aertgeerts has a strong belief in international collaboration.
Erik Briers (new Board Member), MSc, PhD
Erik Briers is a prostate cancer patient, patient representative, member of the EAU (European Association of Urology) prostate cancer guidelines committee and co-author of the EAU guidelines publication. Erik has a PhD in Chemistry from the University of Leuven, Belgium and was CEO of a biotech company. His strong social involvement within patient organisations began after his own prostate cancer diagnosis in 2001. He was Executive Director of the ECPC (European Cancer Patient Coalition) for two years and is currently Board Member of "Wij ook", a Belgian organisation dedicated to inform and educate the public on prostate cancer and to provide patients with assistance. He is also the editor of "PROSTAATinfo", the member magazine.
Evandro de Azambuja (new Board Member), MD, PhD
Evandro de Azambuja is the Head of the Medical Support Team of the Academic Promoting Team located at the Jules Bordet Institute in Brussels, Belgium. He earned his first PhD from the Federal University of Rio Grande do Sul, Porto Alegre, Brazil in May 2007 and his second PhD from the Université Libre de Bruxelles (ULB) in December 2015. His principal interest in oncology is breast cancer. He is involved in the design and conduct of large clinical trials in breast cancer. Dr. de Azambuja is author or co-author of several publications in peer-reviewed journals and is member of several scientific organisations.
Delphine Heenen (new Board Member), LLM
Delphine Heenen, founder and managing director of KickCancer, is a patient advocate in paediatric oncology. She was successively a lawyer (Linklaters), a strategy consultant (Bain & Company) and active in the investment world of renewable energy (TTR energy). Delphine first supported her son Raphaël in his fight against cancer but in January 2017, she decided to move up another gear to fight childhood cancers by working full-time for KickCancer, a public interest foundation working closely with the KickCancer Fund, a Fund dedicated to research in paediatric oncology managed by the King Baudouin Foundation.
Prof. Dr. Yolande Lievens (new Board Member), MD, PhD
Yolande Lievens is a Radiation Oncologist, Chair of the Radiation Oncology Department at the Ghent University Hospital, Belgium (UZ Gent) and Associate Professor in Radiation Oncology at the Ghent University, Belgium. Her clinical focus lies on radiotherapy for thoracic malignancies, but she also has special interest in the role of radiotherapy in haematology and in breast cancer. From April 2016 till April 2018, she was President of ESTRO (European Society for Radiotherapy and Oncology). In view of providing state-of-the-art radiotherapy to all cancer patients who need it, Prof. Lievens is convinced that evidence - clinical as well as economical - is key to sustain innovation in and improve access to radiotherapy within the nowadays often-limited health care budget.
Prof. Dr. Eric Van Cutsem, MD, PhD
Eric Van Cutsem trained in internal medicine and gastroenterology in Leuven and specialised in GI oncology in Leuven, Belgium. He is currently Professor of Internal Medicine at the University of Leuven and is Head of the Clinical Digestive Oncology Unit at the University Hospital Gasthuisberg in Leuven (UZ Leuven). He is also a Board Member of Leuven Cancer Institute and of the Department of Oncology at the University of Leuven. He has a large clinical activity in Leuven and is involved in, and leads, many national and international clinical and translational research projects on gastrointestinal cancer. Prof. Van Cutsem has published more than 340 peer-reviewed-articles, is/has been an editorial board member of numerous prestigious journals and is member of several scientific organisations.
Joris Verlooy, MD
Joris Verlooy is a paediatric hemato-oncologist at the Antwerp University Hospital (UZ Antwerpen). Prior to that he had the same position at the Ghent University Hospital (UZ Gent). He is member of the BSPHO (Belgian Society of Paediatric Haematology Oncology). As such, he is also part of a task force to optimise and oversee information to parents and patients, a joined initiative of the Anticancer Fund and KickCancer, with the help of the BSPHO. This is in accordance with his interests in quality of life, comfort care and palliative care of paediatric cancer patients. In clinical care he also has a special interest in children with central nervous system tumours.
Meet our Advisory Board here